ストックスクリーナーアプリを入手
175.21
1.03%
1.78
前日終値:
$173.43
開ける：
$173.5
24時間の取引高:
182.03K
Relative Volume:
0.16
時価総額：
$10.33B
収益：
$551.35M
当期純損益:
$-189.33M
株価収益率:
-53.23
EPS:
-3.2916
ネットキャッシュフロー:
$-35.09M
1週間 パフォーマンス:
+4.36%
1か月 パフォーマンス:
+8.47%
6か月 パフォーマンス:
+43.49%
1年 パフォーマンス:
+130.90%
1日の値動き範囲:
$172.93
$177.41
1週間の範囲:
$163.13
$176.07
52週間の値動き範囲:
$73.16
$191.62
Glaukos Corp Stock (GKOS) Company Profile
Compare GKOS vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
175.21 | 10.33B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
99.05 | 171.40B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.54 | 119.65B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
297.24 | 114.01B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.47 | 64.45B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.09 | 50.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-28 | 開始されました | UBS | Neutral |
| 2026-07-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corp (GKOS) 最新ニュース
Glaukos Expands Retinal Pipeline With RevOpsis Deal - Orange County Business Journal
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup - ChartMill
Stifel reiterates Glaukos stock rating on strong iDose growth - Investing.com
Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After Solid Q3 iDose Volume Diligence - StreetInsider
Mizuho lifts target for Glaukos stock to USD 190.00 - ad-hoc-news.de
Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery - Glance by Eyes On Eyecare
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Midday Stock Roundup: loanDepot Shares Continue Falling - Orange County Business Journal
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Yahoo Finance
Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes - Glance by Eyes On Eyecare
Enrollment Complete in Glaukos Study of the PRESERFLO MicroShunt - Medical Product Outsourcing
Midday Stock Roundup: Karman Slips - Orange County Business Journal
GKOS Maintained by BTIG -- Price Target Raised to $205 - GuruFocus
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS) - Seeking Alpha
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos: The Second J-Code Rewrites The Risk Math - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - The Globe and Mail
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Barchart.com
Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i - GuruFocus
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Benzinga
Glaukos Reports Positive Phase 4 Results for iDose TR - Orange County Business Journal
Glaukos' iDose TR meets primary goal in phase 4 trial - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Yahoo Finance
Why is Glaukos stock climbing today? - Investing.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - BioSpace
Glaukos licenses rights to Revopsis’ RO-104 for retinal diseases - BioWorld News
Glaukos licenses preclinical tri-specific retinal biologic RO-104 from RevOpsis - AllSci
Glaukos Says Phase 4 Trial of iDose TR Meets Primary Efficacy Endpoint - marketscreener.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - Yahoo Finance
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal - Benzinga
Glaukos (GKOS) Shares Fall 13% Despite Positive Epioxa Trial Res - GuruFocus
Glaukos' Epioxa maintains corneal flattening and visual gains through 3 years in keratoconus - Ophthalmology Times
Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative? - Yahoo Finance
Glaukos slips as insider selling overshadows positive trial data for eye therapy - TradingView
Eli Lilly, Glaukos among market cap stock movers on Thursday - Investing.com
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - BioSpace
Glaukos licenses tri-specific biologic for retinal diseases By Investing.com - Investing.com Nigeria
Glaukos licenses retinal biologic RO-104 from RevOpsis Therapeutics - StreetInsider
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - Yahoo Finance
Glaukos Corp (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
Glaukos Corp (GKOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Navratil Tomas | Officer |
Oct 05 '26 |
Proposed Sale |
164.45 |
1,527 |
251,121 |
0 |
| Navratil Tomas | Officer |
Sep 25 '26 |
Proposed Sale |
154.28 |
1,615 |
249,158 |
0 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Sep 25 '26 |
Sale |
154.28 |
1,615 |
249,158 |
70,818 |
| Navratil Tomas | Officer |
Sep 16 '26 |
Proposed Sale |
166.92 |
1,457 |
243,207 |
0 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Sep 16 '26 |
Sale |
166.92 |
1,457 |
243,204 |
72,433 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Aug 28 '26 |
Sale |
180.67 |
13,744 |
2,483,104 |
73,890 |
| Navratil Tomas | Officer |
Aug 28 '26 |
Proposed Sale |
180.67 |
13,744 |
2,483,098 |
0 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Sale |
190.00 |
2,500 |
475,000 |
37,406 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Option Exercise |
25.77 |
2,500 |
64,425 |
39,906 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Proposed Sale |
190.00 |
2,500 |
475,000 |
0 |
0.49%
6.80%
大文字化:
|
ボリューム (24 時間):